This article is more than 5 years old. Information may no longer be current.

InSite reports quarterly revenue of $5.3 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

InSite Vision reported revenue of $5.3 million in the third quarter compared with $12.1 million for the same period a year ago, according to a press release.

Royalties from Merck on net sales of AzaSite (azithromycin ophthalmic solution) included an additional $3.7 million and $9.3 million in the third quarters of 2013 and 2012, respectively. The decrease in minimum royalty payments was attributed to an amendment in August 2012 to the Merck license regarding payment terms.

Net income was $0.6 million, or less than $0.01 per share, for the third quarter, compared with net income of $5.1 million or $0.04 per share, in the third quarter of 2012. The difference was attributed to the supplemental royalties received from Merck, according to the release.